A long-term comparative trial of cerivastatin sodium, a new HMG-CoA reductase inhibitor, in patients with primary hypercholesterolemia

Clinical Therapeutics

Volumn 20, Issue 3, 1998, Pages 539-548

  Sasaki, Jun ^a   Arakawa, Kikuo ^a   Yamamoto, Kyosuke ^b   Kobori, Shozo ^c   Ageta, Masato ^d   Kono, Suminori ^e  

^a FUKUOKA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b SAGA UNIVERSITY   (Japan)

^c KUMAMOTO UNIV SCHOOL OF MEDICINE   (Japan)

^d Prefectural Nichinan Hospital   (Japan)

^e KYUSHU UNIVERSITY   (Japan)

Author keywords

Cerivastatin sodium; Cholesterol; HMG CoA reductase inhibitors; Hypercholesterolemia

Indexed keywords

CERIVASTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG TOLERANCE; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HYPERCHOLESTEROLEMIA; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; STATISTICAL ANALYSIS; TEST MEAL; TREATMENT PLANNING; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0031878614     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(98)80063-5     Document Type: Article

References (18)

1. Lipid Research Clinics Program: The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA. 1984;251:351-364.
2. Lipid Research Clinics program: The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA. 1984;251:365-374.
3. Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study: Primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia: Safety of treatment, changes in risk factors, and incidence of coronary heart disease. NEJM. 1987;317:1237-1245.
4. The Pravastatin Multinational Study Group for Cardiac Risk Patients. Effects of pravastatin in patients with serum total cholesterol levels from 5.2 to 7.8 mmol/ liter (200 to 300 mg/dl) plus two additional atherosclerotic risk factors. Am J Cardiol. 1993;72:1031-1037.
5. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet. 1994; 344:1383-1389.
6. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hyperlipidemia. NEJM. 1995;333:1301-1307.
7. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. NEJM. 1996;335:1001-1009.
8. Bischoff H, Angerbauer R, Bender J, et al. Cerivastatin: Pharmacology of a novel synthetic and highly active HMG-CoA reductase inhibitor. Atherosclerosis. 1997; 135:119-130.
9. Goto Y, Yasugi T, Nakaya N, et al. Clinical efficacy of a new HMG-CoA reductase inhibitor, BAY w 6228: A dose-finding study among groups by the double blind method. Jpn Pharmacol Ther. 1996;24(Suppl 9): S1297-S1325. In Japanese.
10. Richmond W. Preparation and properties of a cholesterol oxidase from Nocardia sp. and its application to the enzymatic assay of total cholesterol in serum. Clin Chem. 1973;19:1350-1356.
11. Tamaoku K, Ueno K, Akiura K, Ohkura Y. New water-soluble hydrogen donors for the enzymatic photometric determination of hydrogen peroxide. II. N-ethyl-N-(2-hydroxy-3-sulfopropyl)aniline derivatives. Chem Pharm Bull. 1982;30:2492-2497.
12. Warnick GR, Albers JJ. A comprehensive evaluation of the heparin-manganese precipitation procedure for estimating high density lipoprotein cholesterol. J Lipid Res. 1978;19:65-76.
13. Noma A, Hata Y, Goto Y. Quantitation of serum apolipoprotein A-I, A-II, B, C-II, C-III and E in healthy Japanese by turbidimetric immunoassay differences. Clin Chim Acta. 1991;199:147-158.
14. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of lowdensity lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499-502.
15. Saito Y, Goto Y, Nakaya N, et al. Clinical evaluation of CS-514 in hyperlipidemia: A double-blind dose-finding study in three dose groups. J Clin Ther Med. 1987;3: 1445-1472. In Japanese, with English abstract.
16. Goto Y, Yamamoto A, Matsuzawa Y, et al. Clinical usefulness of pravastatin (CS-514) in hyperlipidemic patients. J Clin Exp Med. 1988;146:927-955. In Japanese.
17. Goto Y, Yamamoto A, Arakawa K, et al. Clinical usefulness of MK-733 (simvastatin) in hyperlipidemia. J Clin Exp Med. 1990;153:713-740. In Japanese.
18. Fluvastatin Study Team. Clinical usefulness of fluvastatin (XU 62-320) in hyperlipidemic patients: A phase III double-blind comparative study with pravastatin. J Clin Ther Med. 1995;11:1679-1762. In Japanese, with English abstract.